
AstraZeneca Launches Phase III Trial for COPD Treatment BREZTRI
AstraZeneca has initiated a Phase III trial to study the effects of the triple-combination inhaled therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes in people with chronic…












